In patients with stage 2 CKD , adjusted mean treatment differences versus placebo in changes from baseline in HbA1c at week 24 were -052 % ( 95 % CI -072 to -032 ) for empagliflozin 10 mg and -068 % ( -088 to -049 ) for empagliflozin 25 mg ( both p < 00001 ) .